FDA Grants Bionaut Labs Orphan Drug Designation to BNL-101 for the Treatment of Malignant Gliomas in Pediatric and Adult Patients

LOS ANGELES: LOS ANGELES, June 23, 2021 /PRNewswire/ -- Bionaut Labs, a company focused on revolutionizing the treatment of central nervous system disorders (CNS) with its Bionaut™ precision medicine treatment modality, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for BNL-101...

Click to view original post